Posts Tagged ‘DVT’
It has long been known that estrogen-containing birth control preparations (pill, patch, ring) increase the risk for DVT and PE (venous thromboembolism = VTE). This risk is partially due to the estrogen. However, part of the risk is also due to the type of progestin in these preparations. Read the rest of this entry »
Your patient may inquire whether he/she can take Nattokinase instead of staying on warfarin to prevent future venous thromboembolism; or what you think about the effectiveness of Nattokianse in preventing a first or recurrent DVT or PE. Read the rest of this entry »
A new guideline about the prevention, diagnosis, and treatment of DVT and PE associated with pregnancy was published today by ACOG (American College of Obstetricians and Gynecologists) in its respected series of Practice Bulletins. The bulletin includes detailed reference to thromboprophylaxis in pregnant women with thrombophilia. Read the rest of this entry »
The CDC today published recommendations on use of contraceptive methods for non-breast feeding women in the post-partum period (full text is here). The key recommendations are as follows: Read the rest of this entry »
CT or MRI scans will occasionally detect an incidental iliofemoral DVT, PE or intra-abdominal thrombosis (IVC, portal, splenic, mesenteric or renal vein). This is particularly common in cancer patients undergoing staging CT scans. When such an incidental, asymptomatic venous thromboembolism (VTE) is discovered, the question arises whether the patient should be treated with anticoagulants or not. Read the rest of this entry »
Explanation for Patients
The complex topic of “Length of Anticoagulant Treatment” for patients with VTE is being addressed in a blog entry written for patients, found on the Clot Connect patient education blog (here).
For the Health Care Professional
Well respected treatment guidelines exist [ref 1,2]. Read the rest of this entry »
Good news. Another one of the new oral anticoagulants in development, Apixaban (Eliquis®), has moved forward. On May 20th, 2011, the European Medicines Agency (EMA) approved Eliquis® for DVT prevention after orthopedic surgery (hip and knee replacement) in the 27 countries of the European Community. In the U.S., however, Eliquis® is still some way away from getting FDA approval Read the rest of this entry »
Many people think of DVT and PE as a problem occurring in elderly people, but not in young and apparently healthy individuals. While it is certainly true that they occur more commonly in the elderly and in non-athletic overweight individuals, they can, nevertheless, happen in young, normal weight, and athletic people. Read the rest of this entry »
If you as a health care professional are involved in the management of patients with acute (proximal) DVT, please consider giving the patient (who has leg symptoms ≤ 14 days) an opportunity to be enrolled in the national ATTRACT trial (information on the trial is here).
This NIH-funded, multi-center trial investigates whether catheter-directed thrombectomy (± locally delivered tPA into the clot) Read the rest of this entry »